» Articles » PMID: 29263786

Tumor Cell Dormancy As an Adaptive Cell Stress Response Mechanism

Overview
Journal F1000Res
Date 2017 Dec 22
PMID 29263786
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Metastases are responsible for most cancer-related deaths. The kinetics of tumor relapse is highly heterogeneous, ranging from recurrences shortly after diagnosis to years or even decades after the initial treatment. This subclinical period is known as tumor dormancy, in which residual disease remains in an undetectable state before finally appearing as an overtly proliferative metastasis. Despite recent advances in our understanding of the molecular mechanisms leading to tumor dormancy, it is still a poorly understood phase of cancer progression, which limits opportunities for the design of successful therapeutic interventions. The influence of the tumor microenvironment at the metastatic site and anti-metastatic immune responses have been shown to play a crucial role in the onset and maintenance of metastatic dormancy. However, there is still a significant gap in our understanding of how dormant cells remain viable in a quiescent state for long periods of time. Here, we review the latest experimental evidence shedding light on the biological processes that enable dormant tumor cells to endure the multiple stresses encountered at the metastatic site.

Citing Articles

Proteomic insights into breast cancer response to brain cell-secreted factors.

Ahuja S, Lazar I Sci Rep. 2024; 14(1):19351.

PMID: 39169222 PMC: 11339284. DOI: 10.1038/s41598-024-70386-7.


Emerging Role of Autophagy in Governing Cellular Dormancy, Metabolic Functions, and Therapeutic Responses of Cancer Stem Cells.

Tiwari M, Srivastava P, Abbas S, Jegatheesan J, Ranjan A, Sharma S Cells. 2024; 13(5.

PMID: 38474411 PMC: 10930960. DOI: 10.3390/cells13050447.


Outlook and opportunities for engineered environments of breast cancer dormancy.

Richbourg N, Irakoze N, Kim H, Peyton S Sci Adv. 2024; 10(10):eadl0165.

PMID: 38457510 PMC: 10923521. DOI: 10.1126/sciadv.adl0165.


Dormant cancer cells and polyploid giant cancer cells: The roots of cancer recurrence and metastasis.

Jiao Y, Yu Y, Zheng M, Yan M, Wang J, Zhang Y Clin Transl Med. 2024; 14(2):e1567.

PMID: 38362620 PMC: 10870057. DOI: 10.1002/ctm2.1567.


Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications.

Mora-Rodriguez J, Sanchez B, Sebastian-Martin A, Diaz-Yuste A, Sanchez-Chapado M, Palacin A Int J Mol Sci. 2023; 24(21).

PMID: 37958610 PMC: 10650717. DOI: 10.3390/ijms242115626.


References
1.
Manjili M . The inherent premise of immunotherapy for cancer dormancy. Cancer Res. 2014; 74(23):6745-9. DOI: 10.1158/0008-5472.CAN-14-2440. View

2.
Ghajar C, Peinado H, Mori H, Matei I, Evason K, Brazier H . The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013; 15(7):807-17. PMC: 3826912. DOI: 10.1038/ncb2767. View

3.
Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

4.
Ranganathan A, Ojha S, Kourtidis A, Conklin D, Aguirre-Ghiso J . Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival. Cancer Res. 2008; 68(9):3260-8. PMC: 2587150. DOI: 10.1158/0008-5472.CAN-07-6215. View

5.
Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M . VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell. 2011; 20(6):701-14. PMC: 3241854. DOI: 10.1016/j.ccr.2011.11.002. View